Allergy Therapeutics PLC, a fully integrated commercial biotechnology company specializing in allergy vaccines, has announced the publication of its Notice of 2023 Annual General Meeting. The notice is available electronically on the company's website and has been posted to shareholders. The meeting is a crucial event for shareholders to be informed about the company's performance and future plans.

The company's Chief Executive Officer, Manuel Llobet, and Chief Financial Officer, Shaun Furlong, are the primary contacts for further information. Additionally, Panmure Gordon and ICR Consilium are available for investor relations and corporate communication.

Allergy Therapeutics PLC is a significant player in the field of allergy vaccines, and the Annual General Meeting is an opportunity for shareholders to engage with the company's leadership and gain insights into its strategic direction and financial performance.